622 related articles for article (PubMed ID: 15477200)
1. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
2. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
[TBL] [Abstract][Full Text] [Related]
6. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
7. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
[TBL] [Abstract][Full Text] [Related]
8. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
9. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of beta-thalassemia mutations and their association with allelic sequence polymorphisms at the beta-globin gene cluster in an Eastern Indian population.
Kukreti R; Dash D; E VK; Chakravarty S; Das SK; De M; Talukder G
Am J Hematol; 2002 Aug; 70(4):269-77. PubMed ID: 12210807
[TBL] [Abstract][Full Text] [Related]
11. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
[TBL] [Abstract][Full Text] [Related]
12. Genotypic heterogeneity and correlation to intergenic haplotype within high HbF beta-thalassemia intermedia.
Papachatzopoulou A; Kourakli A; Makropoulou P; Kakagianne T; Sgourou A; Papadakis M; Athanassiadou A
Eur J Haematol; 2006 Apr; 76(4):322-30. PubMed ID: 16519704
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea in the management of thalassemia intermedia.
Karimi M
Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
[TBL] [Abstract][Full Text] [Related]
15. Beta-globin gene cluster polymorphisms are strongly associated with severity of HbE/beta(0)-thalassemia.
Ma Q; Abel K; Sripichai O; Whitacre J; Angkachatchai V; Makarasara W; Winichagoon P; Fucharoen S; Braun A; Farrer LA
Clin Genet; 2007 Dec; 72(6):497-505. PubMed ID: 17894837
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of thalassemia intermedia in Iran.
Akbari MT; Izadi P; Izadyar M; Kyriacou K; Kleanthous M
Hemoglobin; 2008; 32(5):462-70. PubMed ID: 18932071
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
18. Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes.
Ofori-Acquah SF; Lalloz MR; Layton DM
Biochem Biophys Res Commun; 1999 Jan; 254(1):181-7. PubMed ID: 9920754
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
20. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
